P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 1, 1/6/2020
1/6/2020 1/7/2020 1/8/2020 1/8/20201/7/2020 1/7/2020 1/8/2020 1/9/2020 1/9/2020 1/9/2020 1/10/2020
5223:Heartburn/GERD(Donihi, A)
5119:Orientation(Patel, SGrieve, LCulley, C)
5119:RxPedition:CompanyCreation(Culley, CGrieve, L)
5211:CourseIntroduction(Culley, CReynolds,M)
5215:Vaccine-RelatedDisease(Howrie, D)
5211:CommonThreads ofJournalArticles(Culley, C)
5119:Pharmastartupsandsources offunding(Morley, SPatel, S)
5215:Botulism -Infection &Pharmaceutical Use(Howrie, D)
5213:CourseIntroduction– Buildingyour patientcarepractice(Antinopoulos, BMcGivney,MAntypas, SCarroll, JCothrel, SDarrigo, MGabriel, CHake, KMontgomery, JTurco, E)
5215:Sulfonamides &Quinolones(Minnigh,M)
5223: PUD(Donihi, A)
Denotes examination period Denotes professional dress required Grid Page 1
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 2, 1/13/2020
1/13/2020 1/14/2020 1/15/2020 1/15/20201/14/2020 1/14/2020 1/15/2020 1/16/2020 1/16/2020 1/16/2020 1/17/2020
5223:Nausea/Vomiting(Donihi, A)
5119: DrugDiscovery(Patel, SIyer, P)
5211:Experimental StudyDesign(Culley, C)
5215:Enterobacteriaceae(Salmonellosis,Shigellosis,Escherichiacoli andothers,Cholera)andPseudomonaceae(Pseudomonas sp.,Acinetobacter sp., andStenotrophomonassp.)(Falcione,B)
5211:Experimental StudyDesignActivity(Culley, C)
5119:PreclinicalResearch(Safety)(Patel, SGrieve, LCulley, C)
5119:RxPedition:CompoundAuction(Culley, CGrieve, L)
5215:Enterobacteriaceae(Salmonellosis,Shigellosis,Escherichiacoli andothers,Cholera)andPseudomonaceae(Pseudomonas sp.,Acinetobacter sp., andStenotrophomonassp.)(Falcione,B)
5213:Phase 1
5215:PRACTICUM #1:Antibiotic-AssociatedColitis(AAC) &AntibioticQuiz #1(FolateAntagonists,Quinolones0 (Potoski,B)
5227:Session 1 -SBIRT TBL(Berenbrok,LHall, D)
Denotes examination period Denotes professional dress required Grid Page 2
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 3, 1/20/2020
1/20/2020 1/21/2020 1/22/2020 1/22/20201/21/2020 1/21/2020 1/22/2020 1/23/2020 1/23/2020 1/23/2020 1/24/2020
5211:Observational StudyDesign
5215: Multi-DrugResistance(Falcione,B)
5211:Observational StudyDesignActivity(Culley, C)
5119:FormulationDevelopment (Patel, SGrieve, LSant, V)
5119:RxPedition:TPP Table(Culley, CGrieve, LSant, VPatel, S)
5215:AminoglycosideKinetics &Dosing(Howrie, D)
5213:Phase 1
5215:PRACTICUM #2:InfectiousDiarrheas(Falcione,B)
5227:Session 2 -Screeningand Point-of-CareTesting TBL& Skills(Hall, DBerenbrok,L)
Denotes examination period Denotes professional dress required Grid Page 3
Thomas Waters
Martin Luther King Jr Day
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 4, 1/27/2020
1/27/2020 1/28/2020 1/29/2020 1/29/20201/28/2020 1/28/2020 1/29/2020 1/30/2020 1/30/2020 1/30/2020 1/31/2020
5223:Diarrhea/Constipation(Donihi, A)
5119:PreclinicalPK/PD(Patel, SGrieve, LShaik, I)
5119:RxPedition:Calculations Activity(Grieve, LCulley, CPatel, S)
5211:LiteratureEvaluationTools(Culley, C)
5215:Practicum#3A UTI(Howrie, D)
5211: WorkonLiteratureReviewProjects(Culley, C)
5119:Phase 1TrialsIntroduction(Patel, SGrieve, LRohan, L)
5119:RxPedition:Phase 1Trials(Culley, CGrieve, LPatel, S)
5215:IntroductiontoMycobacteria &Antitubercular Agents(Potoski, B)
5213:Phase 1
5215:Practicum#3B: UTI &AntibioticQuiz #2(Aminoglycosides)(Howrie, D)
Denotes examination period Denotes professional dress required Grid Page 4
Thomas Waters
Selecting Your P3 IPPE Rotations456 Salk�
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 5, 2/3/2020
2/3/2020 2/4/2020 2/5/2020 2/5/20202/4/2020 2/4/2020 2/5/2020 2/6/2020 2/6/2020 2/6/2020 2/7/2020
5223:IBS/IBD(Donihi, A)
5119:Phase 1Debrief andDataReview(Grieve, LPatel, SCulley, C)
5119:RxPedition:Phase 1DataReview(Culley, CGrieve, LPatel, S)
5211:SectionWrap-Up(Culley, C)
5215: AnsaMacrolides–Rifamycins(Potoski, B)
5211:IntroductiontoStatistics/DescriptiveStatistics(Reynolds,M)
5219:Practicum 1- All groups(Sant, V)
5119:InvestorPresentationPreparation(Grieve, LPatel, SCulley, C)
5215:Tuberculosis (Potoski,B)
5213: TheRole of thePharmacistin PublicHealth(McGivney,MAntinopoulos, BAntypas, SCothrel, SDarrigo, MFalcione, BGabriel, CHake, KMontgomery, JTurco, ECarroll, J)
5215: Exam#1 ThroughJan 29(Falcione, BPotoski, BMinnigh, MHowrie, D)
Denotes examination period Denotes professional dress required Grid Page 5
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 6, 2/10/2020
2/10/2020 2/11/2020 2/12/2020 2/12/20202/11/2020 2/11/2020 2/12/2020 2/13/2020 2/13/2020 2/13/2020 2/14/2020
5223:EXAM 1
5119:Phase 1InvestorPresentations (Grieve,LCulley, CPatel, S)
5211:IntroductiontoInferentialStatistics(Reynolds,M)
5215:Spirochetes(Howrie, D)
5211:CalculatingStatisticalTests withCategoricalData/BasicBiostatisticsExercise(Reynolds,M)
5119:Phase 1InvestorPresentations (Culley,CGrieve, LPatel, S)
5215:Overview ofFungalOrganismsandInfection(Potoski, B)
5213:Phase 2
5215:AntifungalAgents Part1 (Minnigh,M)
Denotes examination period Denotes professional dress required Grid Page 6
Thomas Waters
Presenting Yourself as a Professional - with Professor Skledar456 Salk�
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 7, 2/17/2020
2/17/2020 2/18/2020 2/19/2020 2/19/20202/18/2020 2/18/2020 2/19/2020 2/20/2020 2/20/2020 2/20/2020 2/21/2020
5223:Clinical andArtificialNutrition(Johnson,H)
5119:Phase 2TrialIntroduction(Grieve, LPatel, S)
5119:RxPedition:InvestmentsFinalized(Culley, CGrieve, L)
5211:LinearRegressionforNumericalOutcomeVariables(Reynolds,M)
5215:Introductionto Mycology(Potoski, B)
5211:Hands-onPracticewithAnalyzingNumericalOutcomeVariables(Reynolds,M)
5119:Phase 2Trial Design(Patel, SGrieve, L)
5215:AntifungalAgents,Part 3 -Amphotericin (Howrie,D)
5213:Phase 2
5215:AntifungalAgents Part2 (Minnigh,M)
Denotes examination period Denotes professional dress required Grid Page 7
Thomas Waters
5227SimulationSBIRTSP8-11:50A402 Salk峙
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 8, 2/24/2020
2/24/2020 2/25/2020 2/26/2020 2/26/20202/25/2020 2/25/2020 2/26/2020 2/27/2020 2/27/2020 2/27/2020 2/28/2020
5223:Obesity &BariatricSurgery(Donihi, A)
5119:Phase 2Debrief andDataReview(Grieve, LPatel, SCulley, C)
5211:LogisticRegressionandSurvivalAnalysis(Reynolds,M)
5215:CommunityFocusedMycosesIncludingTopicalTherapies(Potoski, B)
5211:Hands-onPracticewithRegression(Reynolds,M)
5119:Phase 2PresentationPreperation(Grieve, LCulley, C)
5215:CapstoneDebrief &AntibioticQuiz #3(Antifungals) (Howrie,D)
5213:Phase 2
5215:Capstone(Howrie, D)
5223:NutritionGradedAssessment -attendancerequired
Denotes examination period Denotes professional dress required Grid Page 8
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 9, 3/2/2020
3/2/2020 3/3/2020 3/4/2020 3/4/20203/3/2020 3/3/2020 3/4/2020 3/5/2020 3/5/2020 3/5/2020 3/6/2020
5119:Phase 2BoardMeetings(Culley, CPatel, SGrieve, L)
5211:SampleSize andPower(Reynolds,M)
5215:Practicum4A-Candidiasis(Potoski, B)
5211:Biostatisticsreview(Reynolds,M)
5119:Phase 2BoardMeetings(Culley, CGrieve, LPatel, S)
5215:Practicum4B:Opportunistic Mycoses(Potoski, B)
5213:ExpandingYourCommunityPharmacyPractice:Innovationand PatientCare(Antinopoulos, BMcGivney,MAntypas, SCarroll, JCothrel, SDarrigo, MMontgomery, JKorenoski,AHake, KGabriel, CTurco, E)
5215:EXAMINATION #2ThroughFeb 27(Potoski, BMinnigh, M)
5227:Session 4 -Pharmacotherapy withOlderAdults TBL(Berenbrok,LHall, D)
Denotes examination period Denotes professional dress required Grid Page 9
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 10, 3/9/2020
3/9/2020 3/10/2020 3/11/2020 3/11/20203/10/2020 3/10/2020 3/11/2020 3/12/2020 3/12/2020 3/12/2020 3/13/2020
5211:SPRINGBREAK
5211:SPRINGBREAK
5213:SPRINGBREAK -NO CLASS
Denotes examination period Denotes professional dress required Grid Page 10
Thomas Waters
Spring Break
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 11, 3/16/2020
3/16/2020 3/17/2020 3/18/2020 3/18/20203/17/2020 3/17/2020 3/18/2020 3/19/2020 3/19/2020 3/19/2020 3/20/2020
5223: LiverAnatomy,Physiology,Pathology/DrugInducedLiver Injury(Corey, S)
5119:Phase 3TrialIntroduction(Grieve, LPatel, SCulley, C)
5119:RxPedition:Phase 3Trials(Culley, CGrieve, LPatel, S)
5211:Results andConclusions of Studies(Culley, C)
5215:Introductionto Virology(Howrie, D)
5211:SystematicReviews,Meta-Analyses,PracticeGuidelines(Culley, C)
5219:Practicum -2 (Rohan,LSant, SSant, V)
5119:Phase 3Trials(Grieve, LCulley, CPatel, S)
5215:Practicum#5A:VirologyCases(Howrie, D)
5213:Phase 3
5215:AntiviralAgents Part1 (Minnigh,M)
Denotes examination period Denotes professional dress required Grid Page 11
Thomas Waters
Peer Evaluation of Portfolios456 Salk蜰
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 12, 3/23/2020
3/23/2020 3/24/2020 3/25/2020 3/25/20203/24/2020 3/24/2020 3/25/2020 3/26/2020 3/26/2020 3/26/2020 3/27/2020
5223:AnatomyandPhysiologyofPancreas/Acute andChronicPancreatitis(Corey, S)
5119: DrugMarketingIntroduction(Culley, CGrieve, L)
5211:IntroductiontoEvidence-BasedMedicine(Culley, C)
5215:Virology(Howrie, D)
5211:Evidence-BasedMedicineCase #1(Culley, C)
5119: DrugMarketingPracticum(Culley, CGrieve, L)
5215:Practicum#5B:VirologyCases;AntibioticQuiz #4(Antivirals)(Howrie, D)
5213:Phase 3
5215:Antiviral/AntiretroviralAgents,Part 2(Minnigh,M)
Denotes examination period Denotes professional dress required Grid Page 12
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 13, 3/30/2020
3/30/2020 3/31/2020 4/1/2020 4/1/20203/31/2020 3/31/2020 4/1/2020 4/2/2020 4/2/2020 4/2/2020 4/3/2020
5223: ViralHepatitis 1(Johnson,H)
5119:Phase 3Debrief andDataReview(Patel, SCulley, CGrieve, L)
5119:Phase 2and 3 Test(Culley, CGrieve, LPatel, S)
5211:MediaHealthLiteracy(Culley, C)
5215:Virology
5211:MediaHealthLiteracyActivity(Culley, C)
5119:Phase 4Trials(Culley, CGrieve, LPatel, S)
5119:RxPedition:PresentationPreperations (Culley, CGrieve, LPatel, S)
5215:IntroductiontoParasitology (Schiff, P)
5213:Phase 3 -Last DayOn-Site
5215:EXAMINATION #3ThroughMarch 26(Howrie, DMinnigh, M)
Denotes examination period Denotes professional dress required Grid Page 13
Thomas Waters
Orientation to P3 IPPEs456 Salk�
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 14, 4/6/2020
4/6/2020 4/7/2020 4/8/2020 4/8/20204/7/2020 4/7/2020 4/8/2020 4/9/2020 4/9/2020 4/9/2020 4/10/2020
5223: ViralHepatitis 2(Johnson,H)
5119:Phase 3TrialPresentations (Culley,CPatel, SGrieve, L)
5211:DebriefEvidence-BasedMedicineCase 1(Culley, C)
5215:IntroductiontoParasitology (Schiff, P)
5211:Evidence-BasedMedicineCase #2(Culley, C)
5215:Introductionto HIV(Potoski, B)
5213:LegislativeDay Make-up Day
5227:Session 5 -VulvovagnialCandidiasisTBL (Hall,DBerenbrok,L)
Denotes examination period Denotes professional dress required Grid Page 14
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 15, 4/13/2020
4/13/2020 4/14/2020 4/15/2020 4/15/20204/14/2020 4/14/2020 4/15/2020 4/16/2020 4/16/2020 4/16/2020 4/17/2020
5223:Complications of LiverDisease(Donihi, A)
5119: FDAPresentations (Culley,CGrieve, LPatel, S)
5211:Evidence-BasedMedicine #2debrief(Culley, C)
5215:Virology –HIV(Potoski, B)
5211: Endof CourseActivity(Culley, C)
5119: FDAPresentations (Culley,CGrieve, LPatel, S)
5215:Virology –HIV(Potoski, B)
5213:Envisioningthe FutureofCommunityPharmacyPractice(Antinopoulos, BMcGivney,MAntypas, SBerenbrok,LCarroll, JCothrel, SDarrigo, MMontgomery, JGabriel, CHake, KTurco, E)
5215:PRACTICUM #6:Virology -HIV(Potoski, B)
5227:Session 6 -HepatitisC/FinalAssessment(Berenbrok,LHall, D)
Denotes examination period Denotes professional dress required Grid Page 15
P2 Grid FinalMONDAYGI/NUTR
522310 - 11:50
Salk 402
MONDAYDrug D&D
51191 - 4:50
Salk 402
TUESDAYD Lit Analys
521111 - 11:50
Salk 355
TUESDAYID 25215
1 - 2:20
Salk 355
WEDSD Lit Analys
52118 - 9:50
Salk 402
WEDSDrug D&D
51191 - 4:50
Salk 402
THURSID 25215
1 - 2:20
Salk 456
THURSColloq
2:30 - 3: 20
Salk 456
FRIDAYC PharmPrac 2
5213
See Schedule
WEDSID 25215
10 - 11:50
Salk 402
THURSCase Conf
52279 - 11:50
Salk 402
Week: 16,
Denotes examination period Denotes professional dress required Grid Page 16
